GSK - Tingkat wutah pendapatan YoY sajrone rolas wulan kepungkur gsk.com

Logo perusahaan publik GlaxoSmithKline (GSK)

Growth at GSK plc (GSK) is driven by the success of the Arexvy vaccine and advancements in oncology. The annual sales growth rate (trailing 12 months) confirms this trend, where the value 6.90 reflects the current figure. The business relies on the high margins of mass drug production. The holding's strategy is based on scaling its innovative portfolio following the spin-off of its infectious disease assets.

Wutah dodolan YoY sajrone rolas wulan kepungkur: GlaxoSmithKline plc (GSK) kanggo 11.02.2024 - 16.11.2026

Ringkesan rincian data analitis GlaxoSmithKline plc (GSK)

- rega lan prakiraan konsensus rega:
Analisis kabeh metrik perusahaan:gsk.com (GSK)
Produk merek GlaxoSmithKline

This indicator measures revenue dynamics over the last 12 months, allowing investors to assess the actual pace of business expansion relative to previous periods. By analyzing the 12-month year-over-year revenue growth rate, one can observe the scaling effect of GSK plc (GSK), where high margins from mass vaccine sales following the completion of costly R&D directly transform patent successes into sustainable cash flow growth.